USA flag logo/image

An Official Website of the United States Government

A Novel Class of Topical Pleitropic Anti-Acne Therapeutics

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95841
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
AR060102
Solicitation Year:
N/A
Solicitation Topic Code:
NIAMS
Solicitation Number:
N/A
Small Business Information
SIGNUM BIOSCIENCES
7 DEER PARK DR, STE H MONMOUTH JUNCTION, NJ -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: A Novel Class of Topical Pleitropic Anti-Acne Therapeutics
Agency: HHS
Contract: 1R43AR060102-01
Award Amount: $327,178.00
 

Abstract:

DESCRIPTION (provided by applicant): Acne is a multifactorial disease affecting ~50 million people in the US. Three main factors contribute to the pathogenesis of acne; 1) P. acnes growth 2) P. acnes-induced inflammation and 3) overproduction of sebum, all targets for therapeutic intervention. Treatments, such as antibiotics and benzylperoxide (BPO) are directed at the bacterium P. acnes and retinoids target sebum control. Several antimicrobial and retinoids also possess anti-inflammatory activity. Howe ver, to date a treatment directed at all three components of acne has not been identified. Signum's isoprenylcysteine (IPC) analogs represent a novel class of topical therapeutics that potentially targets all three contributors of acne pathology. Our preli minary results demonstrate IPC analogs inhibit P. acnes growth. In addition, when topically applied, using an in vivo irritant-dermatitis inflammatory model, our results demonstrate IPC analogs have strong anti-inflammatory activity inhibiting neutrophil i nfiltration, edema and erythema of the skin. Preliminary results support a mechanism involving the reduction in keratinocyte inflammatory mediator production. We have extended these observations to in vitro and in vivo P. acnes-induced inflammation models, demonstrating IPC inhibition of several pro-inflammatory cytokines. Lastly, IPC analogs have also been shown to modulate GPCR signaling, suggesting a potential role in regulating sebum control through inhibition of the GPCR melanocortin 5 receptor (MC5R) (critical for sebaceous gland lipogenesis). Based on our previous work, we hypothesize by screening our library of IPC compounds we will be able to identify IPC chemotypes with plieotropic effects to be developed as a novel therapeutic for acne. Structure- activity relationship of these results will lead to proof of principle by identifying, designing and testing candidate compound(s) having the highest combined potency towards each pathological factor, which will be subsequently developed in a Phase II appl ication. PUBLIC HEALTH RELEVANCE: Acne is the most common disorder of the human skin and affects up to 80% of individuals in their lives. Three main factors contributing to the pathogenesis of acne are 1) P. acnes growth 2) P. acnes-induced infl ammation and 3) overproduction of sebum all of which are potential targets for therapeutic intervention. To date a treatment directed at all three components of acne has not been identified. Successful development of this novel class of topical therapeutic s will be the first that potentially target all three contributors of acne pathology.

Principal Investigator:

Joel S. Gordon
7323296344
JSGORDON@SIGNUMBIO.COM

Business Contact:


eperez@signumbio.com
Small Business Information at Submission:

SIGNUM BIOSCIENCES
SIGNUM BIOSCIENCES 7 DEER PARK DR, STE H MONMOUTH JUNCTION, NJ 08852

EIN/Tax ID: 101061574
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No